View in EDS HTML Full Text PDF Full Text

Open-label pilot study of quetiapine treatment for cannabis dependence.

Saved in:
Bibliographic Details
Title: Open-label pilot study of quetiapine treatment for cannabis dependence.
Authors: Mariani, John J. (AUTHOR), Pavlicova, Martina (AUTHOR), Mamczur, Agnieszka K. (AUTHOR), Bisaga, Adam (AUTHOR), Nunes, Edward V. (AUTHOR), Levin, Frances R. (AUTHOR)
Source: American Journal of Drug & Alcohol Abuse. 2014, Vol. 40 Issue 4, p280-284. 5p.
Subjects: Quetiapine, Marijuana abuse, Substance abuse treatment, Drug dosage, Drug side effects, Drug tolerance
Abstract: Background: There are no efficacious pharmacotherapies for cannabis dependence. The effects of quetiapine are well matched to the symptoms of cannabis withdrawal and could be useful in the treatment of cannabis dependence. Objectives: To evaluate quetiapine for the treatment of cannabis dependence and determine the optimal dosing. Methods: In an eight-week open-label outpatient pilot trial, we evaluated the feasibility of quetiapine treatment for cannabis dependence in 15 outpatients. Quetiapine was gradually titrated to 600 mg or the maximum tolerated dose. Results: The mean study retention was 6.5 weeks (±2.3), with 67% of participants completing all eight weeks of the trial. The mean maximum dose achieved was 197 mg/day (range: 25-600 mg/day). Only two of the 15 participants were able to achieve the target dose of 600 mg daily. There were no serious adverse events and no participants were discontinued from the trial due to adverse effects. The most common reported adverse effects were fatigue (80% of participants) and somnolence (47%). From baseline to week 8, the modeled overall decrease in daily dollar value of marijuana was 76.3% (CI: 63.4%, 84.7%). Over the eight weeks of the study, there was a 46.9% (CI: 11%, 68.3%) decrease in urine tetrahydrocannabinol-9-carboxylic acid (THCOOH) levels. Conclusions: These preliminary results are promising in that quetiapine treatment was tolerated by cannabis-dependent patients and associated with decreased cannabis use. The recommended maximum target dose for cannabis-dependent patients is 300 mg daily. These preliminary data support further evaluation of quetiapine as a treatment for cannabis dependence. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 96774376
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Open-label pilot study of quetiapine treatment for cannabis dependence.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Mariani%2C+John+J%2E%22">Mariani, John J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pavlicova%2C+Martina%22">Pavlicova, Martina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mamczur%2C+Agnieszka+K%2E%22">Mamczur, Agnieszka K.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bisaga%2C+Adam%22">Bisaga, Adam</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nunes%2C+Edward+V%2E%22">Nunes, Edward V.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Levin%2C+Frances+R%2E%22">Levin, Frances R.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22American+Journal+of+Drug+%26+Alcohol+Abuse%22">American Journal of Drug & Alcohol Abuse</searchLink>. 2014, Vol. 40 Issue 4, p280-284. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Quetiapine%22">Quetiapine</searchLink><br /><searchLink fieldCode="DE" term="%22Marijuana+abuse%22">Marijuana abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse+treatment%22">Substance abuse treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+dosage%22">Drug dosage</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+tolerance%22">Drug tolerance</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: There are no efficacious pharmacotherapies for cannabis dependence. The effects of quetiapine are well matched to the symptoms of cannabis withdrawal and could be useful in the treatment of cannabis dependence. Objectives: To evaluate quetiapine for the treatment of cannabis dependence and determine the optimal dosing. Methods: In an eight-week open-label outpatient pilot trial, we evaluated the feasibility of quetiapine treatment for cannabis dependence in 15 outpatients. Quetiapine was gradually titrated to 600 mg or the maximum tolerated dose. Results: The mean study retention was 6.5 weeks (±2.3), with 67% of participants completing all eight weeks of the trial. The mean maximum dose achieved was 197 mg/day (range: 25-600 mg/day). Only two of the 15 participants were able to achieve the target dose of 600 mg daily. There were no serious adverse events and no participants were discontinued from the trial due to adverse effects. The most common reported adverse effects were fatigue (80% of participants) and somnolence (47%). From baseline to week 8, the modeled overall decrease in daily dollar value of marijuana was 76.3% (CI: 63.4%, 84.7%). Over the eight weeks of the study, there was a 46.9% (CI: 11%, 68.3%) decrease in urine tetrahydrocannabinol-9-carboxylic acid (THCOOH) levels. Conclusions: These preliminary results are promising in that quetiapine treatment was tolerated by cannabis-dependent patients and associated with decreased cannabis use. The recommended maximum target dose for cannabis-dependent patients is 300 mg daily. These preliminary data support further evaluation of quetiapine as a treatment for cannabis dependence. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=96774376
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3109/00952990.2014.884102
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 280
    Subjects:
      – SubjectFull: Quetiapine
        Type: general
      – SubjectFull: Marijuana abuse
        Type: general
      – SubjectFull: Substance abuse treatment
        Type: general
      – SubjectFull: Drug dosage
        Type: general
      – SubjectFull: Drug side effects
        Type: general
      – SubjectFull: Drug tolerance
        Type: general
    Titles:
      – TitleFull: Open-label pilot study of quetiapine treatment for cannabis dependence.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mariani, John J.
      – PersonEntity:
          Name:
            NameFull: Pavlicova, Martina
      – PersonEntity:
          Name:
            NameFull: Mamczur, Agnieszka K.
      – PersonEntity:
          Name:
            NameFull: Bisaga, Adam
      – PersonEntity:
          Name:
            NameFull: Nunes, Edward V.
      – PersonEntity:
          Name:
            NameFull: Levin, Frances R.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2014
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 00952990
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: American Journal of Drug & Alcohol Abuse
              Type: main
ResultId 1